CAR T-Cell therapy for blood cancer

CAR T-cell therapy is offered at only a few cancer centers in the country. It’s an emerging treatment for aggressive blood cancers, including leukemia and lymphoma. CAR T-cell therapy involves taking blood from a patient and isolating the T-cells (disease-fighting immune cells). They are then sent to a lab where they are re-engineered into “fighter” cells. These cells are frozen, returned to the hospital, and infused back into the patient to begin attacking the cancer.

CAR T-Cell therapy for blood cancer

CAR T-cell therapy is offered at only a few cancer centers in the country. It’s an emerging treatment for aggressive blood cancers, including leukemia and lymphoma. CAR T-cell therapy involves taking blood from a patient and isolating the T-cells (disease-fighting immune cells). They are then sent to a lab where they are re-engineered into “fighter” cells. These cells are frozen, returned to the hospital, and infused back into the patient to begin attacking the cancer.

MR-Linac: Two strengths combined into one groundbreaking device

We are the only cancer center in the region and one of only six in the United States testing and researching the MR-Linac.^* This breakthrough technology provides real-time images of a tumor as the linear accelerator emits radiation beams to the precise location of the cancer. The live images of the tumor allow the radiation to continually target the tumor, even as a patient breathes and moves.

^*Elekta Unity is pending 510(k) premarket clearance and not available for commercial distribution or sale in the U.S.

MR-Linac: Two strengths combined into one groundbreaking device

We are the only cancer center in the region and one of only six in the United States testing and researching the MR-Linac.^* This breakthrough technology provides real-time images of a tumor as the linear accelerator emits radiation beams to the precise location of the cancer. The live images of the tumor allow the radiation to continually target the tumor, even as a patient breathes and moves.

^*Elekta Unity is pending 510(k) premarket clearance and not available for commercial distribution or sale in the U.S.

Assured experience, trustworthy ability

AHN Cancer Institute values innovation. We believe that pioneering research and cutting-edge technology helps us support our patient-first approach to cancer diagnosis and treatment.

Our research includes stereotactic body radiation therapy (SBRT) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Assured experience, trustworthy ability

AHN Cancer Institute values innovation. We believe that pioneering research and cutting-edge technology helps us support our patient-first approach to cancer diagnosis and treatment.

Our research includes stereotactic body radiotherapy (SBRT) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

SBRT: Help manage liver cancer

Approximately 80 percent of patients with liver cancer are not eligible for surgery. SBRT is proven to shrink tumors in patients with inoperable liver cancer. It also works as a bridge to liver transplants. AHN Cancer Institute pioneered the use of SBRT as an option to safely treat these patients.

SBRT: Help Manage Liver Cancer

Approximately 80 percent of patients with liver cancer are not eligible for surgery. SBRT is proven to shrink tumors in patients with inoperable liver cancer. It also works as a bridge to liver transplants. AHN Cancer Institute pioneered the use of SBRT as an option to safely treat these patients.

SBRT also serves as an effective bridge to surgical removal of a tumor, or a liver transplant. Slowing down tumor growth gives transplant-eligible patients more time to wait for a new liver to become available.

HIPEC: Directed treatment, application, and prevention

AHN Cancer Institute is one of the few centers in the country treating patients with advanced abdominal cancers using an innovative treatment called Hyperthermic Intraperitoneal Chemotherapy (HIPEC). The goal of HIPEC is to prevent new cancer growth with strong doses of heated chemotherapy, circulated directly to the abdomen.

HIPEC causes fewer side effects than intravenous chemotherapy. This approach is particularly effective for those with advanced abdominal cancers.

HIPEC: Directed Treatment, Applicatoin, and Prevention

AHN Cancer Institute is one of the few centers in the country treating patients with advanced abdominal cancers using an innovative treatment called Hyperthermic Intraperitoneal Chemotherapy (HIPEC). The goal of HIPEC is to prevent new cancer growth with high doses of chemotherapy, directly applied to the abdomen.

HIPEC causes fewer side effects than intravenous chemotherapy. This approach is particularly effective for those with advanced abdominal cancers.

Collaboration at our core

Our collaborative processes also extend to our colleagues at John Hopkins Medicine, a world-wide leader in cancer research. This brings an added layer of expertise and reassurance to your treatment.

Together, we provide advanced care for all patients with cancer by aligning on best practices, sharing in the latest breakthroughs, and consulting with other experts who conduct first-rate research.

Collaboration at our core

Our collaborative processes also extend to our colleagues at John Hopkins Medicine, a world-wide leader in cancer research. This brings an added layer of expertise and reassurance to your treatment.

Together, we provide advanced care for all patients with cancer by aligning on best practices, sharing in the latest breakthroughs, and consulting with other experts who conduct first-rate research.

Meet with our team at the AHN Cancer Institute if you are interested in participating in our cutting-edge treatment, or are interested in our dedication to around-the-clock care.

BOOK AN APPOINTMENT